As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran
US Decision Expected Before 2020 Ends
Novartis is counting on inclisuran to be a blockbuster after its $9.7bn buyout of the drug's developer, The Medicines Company 
